Lipocine Inc., a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, has announced an exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries Saudi Arabia, Kuwait, the United Arab Emirates (UAE), Qatar, Bahrain, and Oman.   Under the terms of the agreement, Lipocine received an upfront payment from ...